This randomized, double-blind, placebo-controlled clinical trial studied the efficacy and safety of atomoxetine versus placebo for ADHD symptoms in children with autism spectrum disorder (ASD). The study randomized 89 patients ages 6-17 years with ASD and ADHD symptoms to receive either atomoxetine or placebo for 8 weeks. The primary outcome was change in ADHD Rating Scale scores from baseline to 5 and 8 weeks. Secondary outcomes included Clinical Global Impression scales. The study found that atomoxetine was statistically significantly more effective than placebo for reducing ADHD symptoms based on primary and secondary outcome measures. However, the results have limited generalizability due to the study's exclusion of non-white patients and predominance of male patients.